Zeenat Ara¹, Shah Walliullah¹*, Devarshi Rastogi¹, Sandeep Pandey², Shatakshi Pant¹ and Ramesh Mani Tripathi²

¹Department of Orthopaedic Surgery, King George’s Medical University, Lucknow, Uttar Pradesh, India
²Department of Biochemistry, King George’s Medical University, Chowk, Lucknow, Uttar Pradesh, India

*Corresponding Author: Shah Walliullah, Department of Orthopaedic Surgery, King George’s Medical University, Lucknow, Uttar Pradesh, India.

Received: August 08, 2022; Published: September 23, 2022

Abstract

Spinal cord injury (SCI) is a devasting neurological condition producing physical dependency, morbidity, psychological stress and financial burden, Spinal cord injury is characterized by the degradation of motor, sensory and autonomic functions either because of wholly or partially damage in the spinal cord because of trauma. Its a debilitating neurological condition with socio economic impact on affected individuals and the health care system, It completely changed subjects life because it’s a life long treatment and loss of income and patient completely depend on others. According to Ara Z., et al. 2022 SCI is a life threatning process and it greatly effects subjects' quality of life and families, In 1700 BC in an Egyptian surgical papyrus, they describe the frustration of health care professionals in treating a severe spinal cord injury, the Papyrus reported spinal fractures as a ‘‘disease that should not be treated’’.

Most of these studies approach a patient with acute spinal cord injury (ASCI) in one of four manners: corrective surgery or a physical, biological or pharmacological treatment method. clinically, we only provide supportive care for patients with spinal cord injuries. By combining these treatments, researchers attempt to enhance the functional recovery of patients with spinal cord injuries. Advances in the last decade have allowed us to encourage the development of experimental studies in the field of spinal cord regeneration.

Keywords: SCI; Neuroregeneration; Antioxidant; Complete/Incomplete Paraplegia; Decompression

References

1. Farooqui AA. “Potential Neuroprotective Strategies for Experimental Spinal Cord Injury”. In Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases (2010): 151-181.

1. Pinchi E., et al. “Acute spinal cord injury: a systematic review investigating miRNA families involved”. International Journal of Molecular Sciences 20.8 (2019): 1841.
2. Qu J and Zhang H. “Roles of mesenchymal stem cells in spinal cord injury”. Stem cells international (2017).
3. Bracken MB., et al. “A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study”. The New England Journal of Medicine 322 (1990): 1405-1411.
4. Kucher K., et al. “First-in-man intrathecal application of neurite growth-promoting anti-Nogo-A antibodies in acute spinal cord injury”. Neurorehabilitation and Neural Repair 32.6-7 (2018): 578-589.
5. Badhiwala JH., et al. “Global burden of traumatic brain and spinal cord injury”. The Lancet Neurology 18.1 (2019): 24-25.
6. Jain NB., et al. “Traumatic spinal cord injury in the United States, 1993-2012”. JAMA 313.22 (2015): 2236-2243.
7. Singh A., et al. “Global prevalence and incidence of traumatic spinal cord injury”. Clinical Epidemiology 6 (2014): 309.
8. Kang Y., et al. “Epidemiology of worldwide spinal cord injury: a literature review”. Journal of Neurorestoratology 6.1 (2018): 3.
9. James SL., et al. “Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016”. The Lancet Neurology 18.1 (2019): 56-87.
10. Kumar H., et al. “Matrix metalloproteinase-8 inhibition prevents disruption of blood-spinal cord barrier and attenuates inflammation in rat model of spinal cord injury”. Molecular Neurobiology 55.3 (2018): 2577-2590.
11. Thompson C., et al. “The changing demographics of traumatic spinal cord injury: An 11-year study of 831 patients”. The Journal of Spinal Cord Medicine 38.2 (2015): 214-223.
12. Oteir AA., et al. “The epidemiology of pre-hospital potential spinal cord injuries in Victoria, Australia: a six year retrospective cohort study”. Injury Epidemiology 3.1 (2016): 1-8.
13. Rahimi-Movaghar V., et al. “Prevalence of spinal cord injury in Tehran, Iran”. The Journal of Spinal Cord Medicine 32.4 (2009): 428-431.
14. Lehre MA., et al. “Outcome in patients undergoing surgery for spinal injury in an Ethiopian hospital”. Journal of Neurosurgery: Spine 23.6 (2015): 772-779.
15. Ning GZ., et al. “Epidemiological features of traumatic spinal cord injury in Chongqing, China”. The Journal of Spinal Cord Medicine 39.4 (2016): 455-460.
16. Birua GJ., et al. “Epidemiology of spinal injury in northeast India: a retrospective study”. Asian Journal of Neurosurgery 13.4 (2018): 1084.
17. Chhabra HS and Bhalla AM. “Influence of socio-economic status on access to different components of SCI management across Indian population”. Spinal Cord 53.11 (2015): 816-820.
18. Ahuja CS., et al. “Traumatic spinal cord injury”. Nature Reviews Disease Primers 3.1 (2017): 1-21.
19. Jack AS., et al. “Electrical stimulation as a tool to promote plasticity of the injured spinal cord”. Journal of Neurotrauma 37.18 (2020): 1933-1953.
20. Breasted JH. “The Edwin Smith Surgical Papyrus: published in facsimile and hieroglyphic transliteration”. Translation and commentary in two volumes (1991).V
21. Batchelor PE., et al. “Meta-analysis of pre-clinical studies of early decompression in acute spinal cord injury: a battle of time and pressure”. PloS One 8.8 (2013): e72659.
22. Fehlings MG., et al. “Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS)”. PloS One 7.2 (2012): e32037.
23. Bourassa-Moreau É., et al. “Sarcopenia, but not frailty, predicts early mortality and adverse events after emergent surgery for metastatic disease of the spine”. The Spine Journal 20.1 (2020): 22-31.
24. Grassner L., et al. “Charcot spinal arthropathy: an increasing long-term sequel after spinal cord injury with no straightforward management”. Spinal Cord Series and Cases 1.1 (2015): 1-5.
25. Fehlings MG., et al. “A clinical practice guideline for the management of patients with acute spinal cord injury and central cord syndrome: recommendations on the timing (≤ 24 hours versus> 24 hours) of decompressive surgery”. Global Spine Journal 7.3 (2017): 195S-202S.
26. Anjarwalla NK., et al. “The outcome of spinal decompression surgery 5 years on”. European Spine Journal 16.11 (2007): 1842-1847.
27. Schwab ME and Bartholdi D. “Degeneration and regeneration of axons in the lesioned spinal cord”. Physiological Reviews 76.2 (1996): 319-370.
28. Tai PA., et al. “Attenuating experimental spinal cord injury by hyperbaric oxygen: stimulating production of vasculoendothelial and glial cell line-derived neurotrophic growth factors and interleukin-10”. Journal of Neurotrauma 27 (2010): 1121-1127.
29. Huang L., et al. “Effects of hyperbaric oxygen therapy on patients with spinal cord injury: A systematic review and meta-analysis of Randomized Controlled Trials”. Journal of Back and Musculoskeletal Rehabilitation 34.6 (2021): 905-913.
30. Tator CH. “Review of treatment trials in humanspinal cord injury: issues, difficulties, and recommendations”. Neurosurgery 59.5 (2006): 957-987.
31. Chvatal SA., et al. “Spatial distribution and acute anti-inflammatory effects of methylprednisolone after sustained local delivery to the contused spinal cord”. Biomaterials 29.12 (2008): 1967-1975.
32. Chikuda H., et al. “Mortality and morbidity after high-dose methylprednisolone treatment in patients with acute cervical spinal cord injury: a propensity-matched analysis using a nationwide administrative database”. Emergency Medicine Journal 31.3 (2014): 201-206.
33. Fehlings MG., et al. “Efficacy and safety of methylprednisolone sodium succinate in acute spinal cord injury: a systematic review”. Global Spine Journal 7.3 (2017): 116S-37S.
34. Liu Z., et al. “High-dose methylprednisolone for acute traumatic spinal cord injury: a meta-analysis”. Neurology 93.9 (2019): e841-850.
35. Lee JY., et al. “Matrix metalloproteinase-3 promotes early blood-spinal cord barrier disruption and hemorrhage and impairs long-term neurological recovery after spinal cord injury”. The American Journal of Pathology 184.11 (2014): 2985-3000.
36. Samantaray S., et al. “Low dose estrogen prevents neuronal degeneration and microglial reactivity in an acute model of spinal cord injury: effect of dosing, route of administration, and therapy delay”. Neurochemical Research 36.10 (2011): 1809-1816.
37. Wang Y., et al. “Bcl-2 in suppressing neuronal apoptosis after spinal cord injury”. World Journal of Emergency Medicine 2.1 (2011): 38.
38. Lv R., et al. “Polydatin attenuates spinal cord injury in rats by inhibiting oxidative stress and microglia apoptosis via Nrf2/HO-1 pathway”. Life Sciences 217 (2019): 119-127.
39. Tang R., et al. “The inhibition of inflammatory signaling pathway by secretory leukocyte protease inhibitor can improve spinal cord injury”. Cellular and Molecular Neurobiology 40.7 (2020): 1067-73.
40. Geisler FH., et al. “Recruitment and early treatment in a multicenter study of acute spinal cord injury”. Spine 26.24S (2001): S58-67.
41. Geisler FH., et al. “Recovery of motor function after spinal-cord injury-a randomized, placebo-controlled trial with GM-1 ganglioside”. New England Journal of Medicine 324.26 (1991): 1829-1838.
42. Sperling LE., et al. “Galantamine improves functional recovery and reduces lesion size in a rat model of spinal cord injury”. Brain Research 1724 (2019): 146424.
43. Bigford GE., et al. “Effects of ursolic acid on sub-lesional muscle pathology in a contusion model of spinal cord injury”. PloS One 13.8 (2018): e0203042.
44. Kodani A., et al. “Acteoside improves muscle atrophy and motor function by inducing new myokine secretion in chronic spinal cord injury”. Journal of Neurotrauma 36.12 (2019): 1935-1948.
45. Forgione N and Fehlings MG. “Rho-ROCK inhibition in the treatment of spinal cord injury”. World Neurosurgery 82.3-4 (2014): e535-539.
46. Dubreuil CI., et al. “Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system”. The Journal of Cell Biology 162.2 (2003): 233-243.
47. Fehlings MG., et al. “A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury”. Journal of Neurotrauma 28.5 (2011): 787-796.
48. Kahraman S., et al. “Monitoring of serum ionized magnesium in neurosurgical intensive care unit: preliminary results”. Clinica Chimica Acta 334 (2003): 211-215.
49. Bracken MB and Holford TR. “Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery in National Acute Spinal Cord Injury Study II from results modeled in National Acute Spinal Cord Injury Study III”. Journal of Neurosurgery 96 (2002): 259-266.
50. Sperl A., et al. “The role of magnesium in the secondary phase after traumatic spinal cord injury. A prospective clinical observer study”. Antioxidants 8.11 (2019): 509.
51. Cao SE., et al. “Intrathecal Delivery of Ketorolac Loaded in situ Gels for Prolonged Analgesic and AntiInflammatory Activity in Vertebral Fracture”. Tropical Journal of Pharmaceutical Research 15 (2016): 5-11.
52. Hsieh YC., et al. “Protective effect of intrathecal ketorolac in spinal cord ischemia in rats: a microdialysis study”. Acta Anaesthesiologica Scandinavica 51 (2007): 410-414.
53. Dong L., et al. “Ketorolac reduces spinal astrocytic activation and PAR1 expression associated with attenuation of pain after facet joint injury”. Journal of Neurotrauma 30 (2013): 818-825.

55. Ara Z., et al. “Role of Taurine and its Analogs Against Various Disorders and its Beneficial Effects: A Review Article”. Acta Scientific Medical Sciences9 (2022).

Citation

Citation: Shah Walliullah., et al. “Effect of Various Treatment Modalities After Spinal Cord Injury".Acta Scientific Orthopaedics 5.10 (2022): 56-73.

Copyright

Copyright: © 2022 Shah Walliullah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.